Creating a business process that is accurate, predictable, and capable of meeting the changing needs for disclosing information about clinical trials in multiple study registries and results databases is difficult. Companies need to leverage their current clinical trial process, determine if the disclosure steps will be centralized or decentralized, determine how much to leverage technology, and decide whether, and how, to use outside resources. During this session, we will hear how a large pharma, a small biopharmaceutical company, and a device company developed their clinical trial disclosure business process.

1. Call for Abstracts CLINICAL TRIAL DISCLOSURE
“Emeralds of Experience”
presentations learning the landscape and
DUE BY SEPTEMBER 17, 2007 reading the roadmap
November 13-14, 2007 Hyatt Regency Bonaventure Conference Center and Spa, Weston, FL, USA
PROGRAM CHAIRS This conference will provide practical, pharmaceutical and biotech company-based
BARBARA GODLEW, RN experience/advice and a hands-on conference venue for complying with worldwide
Associate Director, Publication Coordination
regulations for public disclosure of clinical trial information. Individuals delivering
and Transparency Compliance Exploratory
Development Communications, Novartis this conference work inside the industry ensuring company compliance with laws
Pharmaceuticals Corporation and regulations governing the public disclosure of clinical trial information.
PAMELA ROSE, RN, BSN, ASQ-CMQOE Knowledge gained from industry-driven experience cannot be overstated.
Director, Clinical Trial Information Registries,
TAP Pharmaceutical Products Inc.
PROGRAM COMMITTEE This Event is Co-located with 4 other DIA Conferences
TRACY BECK, PhD for Added Networking Opportunities!
Global Medical Business Office Consultant; CTR
Results Gatekeeper, Eli Lilly and Company Publication Writing and Building Partnerships
5
cated DIA Outsourcing Summit
Co-lo ts
MARGARET M. COBB, MD
Global Leader of J & J Clinical Registry, PMI Pharmaceutical SIG/DIA PM SIAC Joint Conference: The Future of
Johnson & Johnson Pharmaceutical Research Even Pharmaceutical Project Management – Is a Paradigm Shift Needed?
& Development, LLC
Winning Strategies for Achieving a Quality EDC Clinical Trial Process:
MARY KUSKIN, RPh Sponsor/CRO, Investigator, IRB Approver and IT/IS
Director, Regulatory Affairs
Pharmalink Consulting Inc.
GERARD LYNCH
Global Manager, AstraZeneca Clinical Trials
Website, AstraZeneca WHO SHOULD ATTEND
JOHN C. McKENNEY, Sr. Those who will benefit from attending this program include:
President & CEO, SEC Associates Inc.
ROBERT PAARLBERG, MS Clinical trial sponsors Pharmaceutical industry and academic
Director, Global Regulatory Policy and Intelligence, Independent investigators clinical researchers
UCB, Inc. Biotechnology researchers Clinical research and development departments
Investigator site personnel Investigational review boards/ethics
MICHAEL RUBISON
committees
Senior Director, Global Medical Research Regulatory affairs personnel
and Registration, Abbott Laboratories Clinical quality assurance professionals
Medical communications groups
MAUREEN STRANGE
Associate Medical Business Operations Consultant;
CTR Initiated Gatekeeper,
Eli Lilly and Company
PATRICIA TEDEN, MBA See page 5 for Suggested Abstract Topics and
Independent Consultant Abstract Submission Guidelines
MILEN VRABEVSKI, MD
Medical Director/CEO, Comac Medical Ltd.
THIS PROGRAM WAS DEVELOPED BY THE GOOD CLINICAL PRACTICES
AND QUALITY ASSURANCE CLINICAL TRIAL DISCLOSURE WORKING
G R O U P A N D T H E C L I N I C A L R E S E A R C H , R E G U L AT O RY A F FA I R S , A N D
For further information, contact MEDICAL WRITING SPECIAL INTEREST AREA COMMUNITIES
Ellen Diegel, Program Manager
Phone +1.215.442.6158 / Fax +1.215.442.6199
VISIT WWW.DIAHOME.ORG FOR A %
COMPLETE SCHEDULE OF EVENTS!
Ellen.Diegel@diahome.org DIA, 800 Enterprise Road, Suite 200, Horsham, PA 19044, USA tel: +1-215-442-6100 fax: +1-215-442-6199 email: dia@diahome.org

2. Continuing Education
The Drug Information Association (DIA) has been reviewed and approved as an Authorized Provider by the International Association for Continuing
Education and Training (IACET), 1620 I Street, NW, Suite 615, Washington, DC 20006. The DIA has awarded up to 1.1 continuing education units (CEUs) to
participants who successfully complete this program.
To receive a statement of credit, please visit www.diahome.org. Detailed instructions on how to complete your credit request and download your certifi-
cate will be provided onsite.
Disclosure Policy: It is Drug Information Association policy that all faculty participating in continuing education activities must disclose to the program audience (1) any
real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. Faculty
disclosure will be included in the course materials.
Learning Objectives: At the conclusion of this conference, participants should be able to:
Name the major stakeholders influencing policymaking regarding the disclo- Discuss the required, proposed and voluntary requirements for clinical
sure of clinical trial information trial registration in the United States and other countries described in the
Apply for a ClinicalTrials.gov protocol registration account workshop
Describe how, where, and when to publicly register a clinical trial and to post Describe the clinical trial lifecycle and the relevance to clinical trial
clinical trial results disclosure
Plan a clinical trial disclosure process appropriate for their company use Explain the relationship between registration and the trial publication plan
Differentiate relevant differences between major regulations, recommenda- Describe processes for ensuring the company is prepared for audit
tions, and guidelines worldwide
Special 5-in-1 Plenary Session !
MONDAY • NOVEMBER 12 with the role of the market in health care delivery, contractors
as customers, and the very large amounts spent on R&D.
4:00-6:00 PM REGISTRATION Outsourced costs such as CRO contracts and clinical grants
represent a very large portion of all drug development spending.
Pharmaceutical professionals involved in outsourced activities
TUESDAY • NOVEMBER 13
need to understand the role that business plays, and does not
7:30-8:15 AM REGISTRATION AND play, in the entire process, as well as how the major actors
CONTINENTAL BREAKFAST involved need to interact with one another.
Professor Harold E. Glass has more than twenty-five years’ international
8:15-8:30 AM WELCOME AND OPENING REMARKS
experience in business and in the pharmaceutical industry. He is professor
of health policy at the University of the Sciences in Philadelphia (USP). USP
8:30-9:15 AM Plenary Session has a long legacy in the pharmaceutical industry dating back to University’s
Join your colleagues from all 5 conferences during this special founding in 1821, counting among its distinguished graduates such indus-
plenary session featuring keynote speaker Harold Glass, PhD, try giants as Lilly, Wyeth, Rorer, Smith, Kline, Burroughs, Wellcome,
followed by a spirited Q&A session. Warner, Lambert, McNeil and many others. He is also senior research fel-
low at the Centre for Evidence Based Policy at Queen Mary, University of
London.
Added Feature!
Shared refreshment breaks, luncheons, and networking reception Dr. Glass holds a MSc (Econ.) from the London School of Economics and a
PhD from the University of North Carolina. He has served on the faculties
allow for extensive multidisciplinary networking opportunities
of the University of North Carolina and University of Zurich, and has pub-
among attendees
lished widely in the areas of business strategy and drug development.
Keynote Address Professor Glass is the founder of DataEdge, LLC, which he sold in 2001 to
DRUG DEVELOPMENT AS A BUSINESS: THE ROLE OF IMS Health. DataEdge was a company focusing on drug development and
pharmaceutical marketing.
OUTSOURCING
Harold Glass, PhD, Professor, Health Policy, University of the
Sciences in Philadelphia; President, TTC, LLC 9:15-9:45 AM Q&A Session with Keynote Speaker
Pharmaceutical drug development is part of a distinctive global
business, distinguished by: the interaction of health care equity 9:45-10:15 AM REFRESHMENT BREAK
Program Agenda for Clinical Trial Disclosure
10:15-10:30 AM WELCOME FROM PROGRAM CHAIRPERSONS Pamela Rose, RN, BSN, ASQ-CMQOE
Barbara Godlew, RN Director
Associate Director, Publication Clinical Trial Information Registries
Coordination and Transparency Compliance TAP Pharmaceutical Products Inc.
Exploratory Development Communications
Novartis Pharmaceuticals Corporation
2

3. 10:30 AM-12:00 PM SESSION 1 UNDERSTANDING A NEW STREET MAP: FDA REVITALIZATION
ACT AND CLINICAL TRIAL DISCLOSURE FROM A LEGISLATURE'S
CLINICAL TRIAL LANDSCAPE AND LIFECYCLE: POINT OF VIEW
THE RELATIONSHIP BETWEEN DISCLOSURE AND THE Speaker Invited
TRIAL PUBLICATION PLAN
CHAIRPERSONS 3:00-3:30 PM REFRESHMENT BREAK
Barbara Godlew, RN
Robert Paarlberg, MS 3:30-5:00 PM SESSION 3
Director, Global Regulatory Policy and Intelligence, UCB, Inc.
AFTER THE TRIAL IS COMPLETED: WHAT, WHEN,
The relationship between clinical trial disclosure and the publication WHERE, AND HOW TO POST TRIAL RESULTS
plan for congress abstracts/posters and completed study manuscript CHAIRPERSONS
are closely intertwined. This session will examine some of the aspects
Tracy Beck, PhD
clinical teams should consider when writing a study protocol as well Global Medical Business Office Consultant; CTR Results
as identifying key stakeholders to include in the publication planning Gatekeeper, Eli Lilly and Company
process. Attendees will also gain knowledge on how the patients,
Milen Vrabevski, MD
families, and advocates view public disclosure of clinical trial proto- Medical Director/CEO, Comac Medical Ltd.
cols and results and how public disclosure may impact publication
planning. The biopharmaceutical industry has used clinical trial registries and
results databases as one way to increase clinical trial transparency
FROM THE EDITOR’S DESK: HOW MUCH IS TOO MUCH? and public trust. Up until recently, the emphasis has been on reg-
Paul W. Ladenson, MD istering trials at initiation, but now the focus has shifted towards dis-
Editor-in-Chief, The Journal of Clinical Endocrinology & closing results. This session will examine external stakeholders who
Metabolism, The Endocrine Society are shaping the landscape of trial disclosure and what potholes to
look out for. Attendees will learn what, when, and how to post
LANDSCAPES AND LIFECYCLES: FROM THE PERSPECTIVE OF THE results summaries, as well as how to avoid risks of off-label promo-
PUBLICATION PLAN tion when creating the summaries for public disclosure.
Barbara Godlew, RN
Robert Paarlberg, MS BRIEF OVERVIEW OF CURRENT REQUIREMENTS FOR POSTING
RESULTS
THE PATH TOWARDS ACCESS AND TRANSPARENCY: Pamela Rose, RN, BSN, ASQ-CMQOE
THE PATIENTS’ POINT OF VIEW WHAT, WHERE, AND HOW TO POST RESULTS
Pat Furlong Tracy Beck, PhD
President, Parent Project Muscular Dystrophy
HOW TO AVOID THE RISKS OF OFF-LABEL PROMOTION IN
RESULTS SUMMARIES
12:00-1:30 PM LUNCHEON
Bob Naidus, JD
Senior Pharmaceutical Counsel, Novartis Pharmaceuticals
1:30-3:00 PM SESSION 2 Corporation
STAKEHOLDER STREET MAPS: A WORLDWIDE OVERVIEW
5:30-6:45 PM NETWORKING RECEPTION
TO CLINICAL TRIAL DISCLOSURE
SPONSORED BY THE GOOD CLINICAL PRACTICES
CHAIRPERSONS
AND QUALITY ASSURANCE CLINICAL TRIAL
Gerard Lynch DISCLOSURE WORKING GROUP AND THE
Global Manager, AstraZeneca Clinical Trials Website
CLINICAL RESEARCH, REGULATORY AFFAIRS AND
Michael Rubison, PhD MEDICAL WRITING SPECIAL INTEREST AREA
Senior Director, Global Medical Research and Registration,
COMMUNITIES
Abbott Laboratories
This session provides an introduction to the major themes of the con-
ference and provides an overview of the laws and policies associated WEDNESDAY • NOVEMBER 14
with transparency of clinical trial registration and results disclosure.
This overview will include US federal and state legislation, interna- 7:30-8:30 AM REGISTRATION AND
tional policies and institutional agreements for both required and CONTINENTAL BREAKFAST
voluntary compliance, and the key issues that have driven clinical
trial transparency. The international research and regulatory commu- 8:30-10:00 AM SESSION 4
nity has responded with a large array of databases and database
standards proposed by international, national, regional healthcare READING AND FOLLOWING THE ROAD MAP: PUBLIC
and regulatory groups, pharmaceutical companies, academic institu- REGISTRATION OF CLINICAL PROTOCOL INFORMATION
tions, professional societies, patient advocate and therapeutic CHAIRPERSONS
specialty groups. Barbara Godlew, RN
Maureen Strange
KEY MILESTONES AND ISSUES: A CHRONOLOGICAL HISTORY OF
Associate Medical Business Operations Consultant; CTR Initiated
CLINICAL TRIAL DISCLOSURE Gatekeeper, Eli Lilly and Company
Gerard Lynch
Michael Rubison, Phd Passed, pending, and proposed clinical trial registry legislation pro-
vides an array of confusing and sometimes conflicting articles and
3

4. requirements for both the end users and the registry administrators. Pamela Rose, RN, BSN, ASQ-CMQOE
This session will provide attendees with clarity on recent develop-
State of Maine regulations require that publicly disclosed clinical
ments in federal legislation and challenges the staff at the National
trial information must be “reliable, accurate and true.” The FDA
Library of Medicine face in complying with the requirements.
Revitalization Act bill currently pending in Congress declares that clin-
Attendees will also gain knowledge in the functional use of
ical trial registry and results database information “shall not be false
ClinicalTrials.gov as we build a record in the registry, step-by-step,
or misleading in any particular.” Finally, the IFPMA statement on
and answer audience questions during this process.
clinical trial disclosure calls for companies to “establish a process of
FINDING AND UNFOLDING THE MAP: LEGISLATION verification” and to “make public how they will adhere to” the stan-
SURROUNDING CLINICALTRIALS.GOV dards defined in the statement. Collectively, these statements build a
Rebecca Williams, PharmD compelling argument for instituting a robust audit program to assess
Assistant Director, ClinicalTrials.gov, National Library your organization’s trial disclosures. This session includes an overview
of Medicine of the key components comprising a sound clinical trial disclosure
audit. The highlight of the session consists of a panel discussion
YES! YOU CAN REGISTER A TRIAL TO CLINICALTRIALS.GOV
featuring industry professionals who have been audited or have
WITHOUT AGLOBAL POSITIONING SYSTEM AND WE’LL SHOW
conducted audits of clinical trial disclosures. Attendees are invited
YOU HOW !!!
to come armed with their most pressing questions to pose to our
Annice Bergeris
Information Research Specialist, National Library of Medicine panelists on this timely and critical topic. Participants will leave this
(assistance provided by Barbara Godlew and Maureen Strange) session with increased understanding and appreciation of how to
prepare for, and what to expect during, a clinical disclosure audit.
10:00-10:30 AM REFRESHMENT BREAK
PANELISTS
10:30 AM-12:00 PM SESSION 5 Auditee Perspective
Shawn M. Pelletier
HERDING CATS THROUGH CANYONS: DEVELOPING A
Associate Director R&D Operations
COMPANY PROCESS FOR PUBLIC DISCLOSURE Bristol-Myers Squibb Company
CHAIRPERSONS
Valerie V. Phillips, MA
Margaret M. Cobb, MD, PhD Manager Clinical Trial Disclosure
Global Leader of J & J Clinical Registry, Johnson & Johnson Pfizer Inc
Pharmaceutical Research & Development, LLC
Patricia Teden, MBA Auditor Perspective
Independent Consultant John C. McKenney, Sr.
Beat E. Widler, PhD
Creating a business process that is accurate, predictable, and capable of
Global Head of Clinical Quality Assurance
meeting the changing needs for disclosing information about clinical trials
F. Hoffmann-La Roche
in multiple study registries and results databases is difficult. Companies
need to leverage their current clinical trial process, determine if the disclo-
sure steps will be centralized or decentralized, determine how much to 3:00-3:30 PM REFRESHMENT BREAK
leverage technology, and decide whether, and how, to use outside
resources. During this session, we will hear how a large pharma, a small 3:30-5:00 PM SESSION 7
biopharmaceutical company, and a device company developed their clini-
cal trial disclosure business process.
“EMERALDS OF EXPERIENCE”
HERDING BIG PHARMA CATS … AVOIDING ACCIDENTS: CLINICAL TRIAL DISCLOSURE
Margaret M. Cobb, MD, PhD LESSONS LEARNED
CHAIRPERSON
SMALL PHARMA: THE CATS WITH MANY HATS
Anthony K. Taylor, Sr. Mary Kuskin, RPh
Clinical Operations Coordinator, Targanta Therapeutics Director, Regulatory Affairs, Pharmalink Consulting Inc.
Corporation The field of clinical trial disclosure has expanded dramatically in
the last ten years. There has been a steady increase in the reach
A DEVICE COMPANY AND COMBINATION PRODUCTS PERSPECTIVE
Lisa Griffin Vincent, PhD, MA of stakeholders, regulations and experience on a global scale. The
Senior Director, Corporate Clinical Research & Development, strategy for posting and maintaining clinical trial information finds a
Medtronic Inc. place in the overall development and lifecycle strategy for biophar-
maceutical and medical device companies. This session will highlight
12:00-1:30 PM LUNCHEON individuals’ experiences along this path to share the practical aspects
of balancing regulation compliance with presentation of meaningful
1:30-3:00 PM SESSION 6 information on clinical trial databases.
ARE YOU READY? PREPARING FOR AUDIT OF CLINICAL
TRIAL DISCLOSURES
CHAIRPERSONS 5:00 PM CONFERENCE ADJOURNED
John C. McKenney, Sr.
President & CEO, SEC Associates Inc.
Statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the Drug Information Association.
Speakers and agenda are subject to change without notice.
Recording of information, in any type of media, is prohibited at all DIA events without prior written consent from DIA.
4

5. “Emeralds of Experience” Information
The Drug Information Association (DIA) is offering a unique opportunity for presenters at The Clinical Trial Disclosure “Emeralds of Experience” session is sched-
the DIA Clinical Trial Disclosure conference in Weston, FL. uled for Wednesday, November 14, 2007 at 3:30 pm.
A podium session will provide those in the clinical trial disclosure field an opportunity to Those interested in participating in the 15-minute podium presentation
share their successes, challenges, and “Emeralds of Experience” on various topics with session should submit an abstract on the topic and information that
their DIA Clinical Trial Disclosure colleagues. Participants can share their experiences and will be presented. Due to the limited time available for podium presen-
“emeralds” by developing a 15-minute presentation. tations, only 4 (four) “Emeralds” will be accepted. A subset of the
Suggested Abstract Topics: program committee will review and select from the topics submitted,
if necessary. For those interested in submitting a poster, authors
Stakeholder Street Maps: A Worldwide Overview to Clinical Trial Disclosure Law
should submit an abstract according to the Guidelines for Abstract
Reading and Following the Road Map: Public Registration of Clinical Protocol
Submission below.
Information
After the Trial is Completed: What, When, Where, and How to Post Trial Results DEADLINE FOR SUBMISSIONS IS SEPTEMBER 17, 2007.
Clinical Trial Landscape and Lifecycle: The Relationship between Registration and
the Trial Publication Plan ALL ENTRIES MUST BE SUBMITTED ONLINE.
Herding Cats through Canyons: Developing a Company Process for Public Disclosure http://www.diahome.org/DIAHOME/GetInvolved/
Are You Ready? Preparing for Audit of Public Disclosure Processes AbstractSubmissionLauncher.aspx
Guidelines for Abstract Submission
All abstracts must be received by September 17, 2007. Authors of selected abstracts 1. At time of electronic submission of abstracts, all speakers must
will be notified by September 28, 2007. Please provide the following information complete the speaker disclosure section of the electronic submission
using the online abstract form: form.
2. Preference will be given to submitted abstracts that address real-life
PRIMARY TOPIC AREA
applications and case studies.
SPEAKER NAME (Degrees, job title) 3. Final PowerPoint presentation for all accepted abstracts will be due
AFFILIATION (Mailing address, phone number, fax number, eMail) to DIA by October 23, 2007 to be reviewed by the committee and
included in the attendee registration packet. Should you choose to
PRESENTATION TITLE submit an abstract for consideration, please mark your calendars
SUMMARY (approximately 2-3 sentences) suitable for inclusion in preliminary program, with this deadline.
if selected 4. Final PowerPoint presentations for all accepted abstracts may have
LEARNING OBJECTIVES (Please provide two learning objectives to inform the learner a company logo on slide number one. Any company logo appearing
of what he/she should be able to do after attending your session. on any other slides will be removed by DIA.
5. Time allotted for individual presentations will be approximately
ABSTRACT (300 words or less) 15-20 minutes. Final timing will be determined by the session chair
and based on the number of presentations selected for the session.
DISCLOSURE INFORMATION 6. DIA will provide complimentary conference attendance for the
All speakers must disclose any significant financial interest or other relationship selected presenter.
with the manufacturer(s) of any commercial product(s) and/or providers of commercial 7. Please note: Only one presenter per presentation will be allowed.
services discussed in an educational presentation, as well as any discussion of Any exceptions to this policy must be discussed with the DIA office
unlabeled or unapproved drugs or devices. in advance.
TRAVEL AND HOTEL The most convenient airport is Fort Lauderdale/Hollywood UNITED AIRLINES & US AIRWAYS
International Airport and attendees should make airline reservations as early as Save through Area Pricing and Discount Fees
possible to ensure availability. The Hyatt Regency Bonaventure Conference
Center and Spa is holding a block of rooms at the reduced rate below until To obtain schedule information and the best fares, call United Airlines’s
October 22, 2007, for the DIA event attendees. Room availability at this rate Specialized Meeting Reservations Center at 1-800-521-4041. Make sure you
is guaranteed only until this date or until the block is filled. refer to Meeting ID Number 571AK. Dedicated reservationists are on duty 7
Single $189 Double $214 days a week from 8:00 AM to 10:00 PM EST.
Please contact the Conference Center by telephone at +1-954-616-1234 or This special offer applies to travel on domestic segments of all United Airlines,
+1-800-233-1234 and mention the DIA event. The hotel is located at 250 United Express, PED, and United code share flights (UA*, operated by US
Racquet Club Road, Weston, FL 33326, USA. Airways, US Airways Express and Air Canada).
GROUP DISCOUNTS* Register 3 individuals from the same company and receive complimentary registration for a 4th! All 4 individuals must register and prepay at the
same time – no exceptions. DIA will apply the value of the lowest applicable fee to this complimentary registration; it does NOT include fees for optional events or DIA mem-
bership. You may substitute group participants of the same membership status at any time; however, administrative fees may be incurred. Group registration is not available
online and does not apply to the already-discounted fees for government or charitable nonprofit/academia.
To take advantage of this offer, please make a copy of this registration form for EACH of the four registrants from your company. Include the names of all four group
registrants on each of the forms and return them together to DIA.
Participants with Disabilities: DIA event facilities and overnight accommodations are accessible to persons with disabilities. Services will be made available to
sensory-impaired persons attending the event if requested at least 15 days prior to event. Contact the DIA office to indicate your needs. 5

6. Drug Information Association www.diahome.org
CLINICAL TRIAL DISCLOSURE CALL FOR ABSTRACTS
“Emeralds of Experience” presentations
learning the landscape and DUE BY SEPTEMBER 17
reading the roadmap
5 Co-located Events for Added Networking Opportunities!
Hyatt Regency Bonaventure Conference DIA Outsourcing Summit
Center and Spa, Weston, FL, USA Publication Writing and Building Partnerships
PMI Pharmaceutical SIG/ DIA PM SIAC Joint Conference: The Future of
NOVEMBER 13-14, 2007 | Event ID #07039 Pharmaceutical Project Management – Is a Paradigm Shift Needed?
Winning Strategies for Achieving a Quality EDC Clinical Trial Process
MEMBER EARLY BIRD Register by OCT. 23, 2007 SAVE $175
Register online or fax this page to +1-215-442-6199 DRUG INFORMATION ASSOCIATION
800 Enterprise Road, Suite 200
Horsham, PA 19044-3595 USA
CONTACT & TABLETOP EXHIBIT INFORMATION
Attendees may visit the tabletop exhibits during the event and during receptions
(if applicable).
Event information: Contact Ellen Diegel at the DIA office by telephone +1-215-442-
6158, fax +1-215-442-6199 or email Ellen.Diegel@diahome.org.
Tabletop exhibit information: Contact Erin Gilliland, Exhibits Associate, at the DIA
office by telephone +1-215-442-6149, fax +1-215-442-6199 or email Erin.Gilliland@
diahome.org. For tabletop exhibit space, please check the box below.
To receive a tabletop exhibit application, please check.
GROUP DISCOUNTS (not available online or on already discounted fees)
Register 3 individuals from the same company and receive complimentary registration
for a 4th! All 4 individuals must register and prepay at the same time – no exceptions.
See page 5 for complete details.
Registration Fees If DIA cannot verify your membership upon receipt of registration REGISTRATION FORM Do not remove mailing label. Please return this entire page. 07039
form, you will be charged the nonmember fee. Registration fee includes refreshment breaks, PLEASE CONSIDER THIS FORM AN INVOICE
luncheons, and reception (if applicable), and will be accepted by mail, fax, or online. Please check the applicable category:
Academia Government Industry CSO Student (Call for registration information)
MEMBER EARLY-BIRD OPPORTUNITY On or before After
Available on nondiscount member fee only OCT. 23, 2007 OCT. 23, 2007
Last Name Check if part of group registration First Name M.I.
Member Fee US $1165 US $1340
Degrees Dr. Mr. Ms.
Join DIA now to qualify for the early-bird MEMBERSHIP
member fee! www.diahome.org/en/Membership/ US $ 130 Job Title
AboutMembership/AboutMembership
To qualify for the early-bird discount, registration form and accompanying payment must be Company
received by the date above. Does not apply to government/academia/nonprofit members.
Address As required for postal delivery to your location Mail Stop
Nonmember Fee US $1470
A one-year membership to DIA is available to those paying a NONMEMBER registration City State Zip/Postal Country
fee. If paying a nonmember fee, please indicate if you do, or do not, want membership.
email Required for confirmation
I want to be a DIA member I do NOT want to be a DIA member
Discount Fees MEMBER NONMEMBER* Phone Number Fax Number Required for confirmation
Government (Full-time) US $ 300 US $ 430
Group Registrant #2 Last Name First Name Completed form required for each group registrant
Charitable Nonprofit/Academia (Full-time) US $ 675 US $ 805
*If paying a nonmember fee, please check one box above, indicating whether you want membership. Group Registrant #3 Last Name First Name Completed form required for each group registrant
CANCELLATION POLICY: On or before NOVEMBER 6, 2007 Group Registrant #4 Last Name First Name Completed form required for each group registrant
Administrative fee that will be withheld from refund amount:
Member or Nonmember = $200 PAYMENT OPTIONS Register online at www.diahome.org or check payment method
Government or Academia or Nonprofit (Member or Nonmember) = $100 CREDIT CARD number may be faxed to: +1-215-442-6199. You may prefer to pay by check or bank transfer since
Tutorial (if applicable) = $50 non-U.S. credit card payment will be subject to the currency conversion rate at the time of the charge.
Cancellations must be in writing and be received by the cancellation date above. Visa MC AMEX Exp Date _______________________________________
Registrants who do not cancel by that date and do not attend will be responsible for
the full registration fee paid. Registrants are responsible for cancelling their own hotel
Card # _______________________________________________________________________________
and airline reservations. You may transfer your registration to a colleague at any time Name (printed) _________________________________________________________________________
but membership is not transferable. Please notify DIA of any such substitutions as soon Signature ____________________________________________________________________________
as possible. Substitute registrants will be responsible for nonmember fee, if applicable.
CHECK drawn on a US bank payable to and mailed along with this form to: Drug Information Association Inc, P.O. Box
DIA reserves the right to alter the venue, if necessary. If an event is cancelled, 95000-1240, Philadelphia, PA 19195-1240, USA. Please include a copy of this registration form to facilitate identification
DIA is not responsible for any airfare, hotel or other costs incurred by registrants. of attendee.
I cannot attend but please keep me informed of DIA’s future events. BANK TRANSFER When DIA completes your registration, an email will be sent to the address on the registration form
with instructions on how to complete the Bank Transfer. Payment should be made in US dollars. Your name and company,
(requires completion of name, postal address and email address on this form)
as well as the Event I.D. # must be included on the transfer document to ensure payment to your account.